DVRG RNS10 Feb 2021 07:14
DeepVerge PLC
("DeepVerge" or "the Company")
DeepVerge expands and adds two virus containment laboratories
Additional laboratory space added for Skin Trust Club in response to a 95% conversion rate in pre-registration for personalised skincare Home Test Kit in the first 10 days
DeepVerge (LSE:DVRG.L), the environmental and life science AI company, announces the addition of two Containment Level 3 (CL3) laboratories at the Company's York, UK HQ facilities, creating a Centre of Excellence for the EcowaterOS consortium, Labskin initiatives, and increases laboratory space in preparation for the launch of the Skin Trust Club, later this quarter.
The Centre of Excellence expands on the successful product testing using Labskin with the SARS-CoV-2 virus with University of Aberdeen, Public Health England, University of Liverpool, Cork Institute of Technology and the work completed with industry partners including Dell Technologies, Unilever and the Water Rising Institute.
The CL3 laboratories will be focused on three areas:
1. Labskin is a key partner with the Liverpool Tropical School of Medicine and Unilever in a multi-year project, the Strength in Places partnership initiative, to create specialist, commercially sustainable research platforms for infectious disease therapeutics in north-west England. The project will see an expansion of Labskin COVID-19 related services to provide clients with the ability to test their soaps, washes and sanitisers and their effectiveness against COVID-19 and other infectious diseases.
2. Further development alongside partners, such as the Aptamer Group, Tyndall Foundries and a number of undisclosed partners to investigate new variants of SARS-CoV-2 by adding a multiplex nano-chip to test for a range of infectious viruses and bacteria on a single chip for the MicrotoxPD range of equipment for detection and identification of SARS-CoV-2, E.coli, Legionella and Cryptosporidium.
3. Continued In-house development of the PulMoBioMed breathalyser condensate on the identification of a variety of respiratory diseases from influenza to SARS-CoV-2, as well as delivering a diagnostic fingerprint for biomarkers relating to diseases where there are no specific and sensitive diagnostic methods available and prognosis is difficult. Further details on this will be provided at a later date.
Retrofitting has begun with Modern Water equipment to add to the range of real-time surveillance services in Water Monitoring. New services for Modern Water clients will include standard tests associated with dangerous pathogens, including contagious infections as well as community detection of opioids. Future services will include real-time monitoring and identification of small and large molecules within the pharmaceutical sector during bio-processing.
Gerard Brandon, CEO of DeepVerge, commented:
The Centre of Excellence and the addition of two CL3 l